Zonas comunes

Motivated by the aforementioned studies, injectable biomaterials have recently become a more appealing TE treatment to attenuate LV remodeling via myocardial wall stabilization; their injectable nature allows for non-invasive delivery, potentially via

! %&!

catheter. A variety of natural and synthetic hydrogels have been investigated to provide mechanical stability to the myocardium post-MI; a comprehensive review of these techniques can be found in Chapter 3 [66]. While several materials have been studied, there remains a lack of understanding of the mechanism involved in their success in limiting remodeling. As discussed, myocardial function is dependent on the physical properties of the myocardium, which are altered during dynamic remodeling; local changes to the ECM may lead to increased susceptibility of the myocardium to global geometric changes (e.g., dilation and thinning of the myocardial wall) making it difficult to maintain normal function. It is important to consider the alterations that occur throughout the progression of remodeling when engineering a treatment including: 1) the degree of mechanical support needed and 2) the duration of treatment to limit maladaptive alterations. This dissertation will focus on material design to fulfill these requirements by designing novel hydrogel systems with tunable mechanical and degradation properties, and investigating their efficacy in attenuating LV remodeling toward the prevention of maladaptive changes and HF following MI.

! %'!

References:

[1] Tortora GJ ,Grabowski SR. The cardiovascular system: the heart. In: Roesch B, editor. Principles of Anatatomy and Physiology. Hoboken: John Wiley & Sons, Inc, 2003. p.659.

[2] Fomovsky GM, Thomopoulos S, Holmes JW. Contribution of extracellular matrix to the mechanical properties of the heart. J Mol Cell Cardiol 2010;48:490.

[3] Mukherjee S VJ, Ravichandran R, Ramakrishna S, Raghunath M. Multimodal biomaterial strategies for regeneration of infarcted myocardium. J Mater Chem 2010;20:8819.

[4] Cleutjens JP, Creemers EE. Integration of concepts: cardiac extracellular matrix remodeling after myocardial infarction. J Card Fail 2002;8:S344.

[5] Hein S, Schaper J. The extracellular matrix in normal and diseased myocardium. J Nucl Cardiol 2001;8:188.

[6] Ju H, Dixon IM. Extracellular matrix and cardiovascular diseases. Can J Cardiol 1996;12:1259.

[7] Buckberg GD. Basic science review: the helix and the heart. J Thorac Cardiovasc Surg 2002;124:863.

[8] Sengupta PP, Korinek J, Belohlavek M, Narula J, Vannan MA, Jahangir A, Khandheria BK. Left ventricular structure and function: basic science for cardiac imaging. J Am Coll Cardiol 2006;48:1988.

[9] Coghlan C, Hoffman J. Leonardo da vinci’s flights of the mind must continue: cardiac architecture and the fundamental relation of form and function revisited. Eur J Cardiothorac Surg 2006;29S:S4.

! %(!

[10] Dobaczewski M, Bujak M, Zymek P, Ren G, Entman ML, Frangogiannis NG. Extracellular matrix remodeling in canine and mouse myocardial infarcts. Cell Tissue Res 2006;324:475.

[11] Dobaczewski M, Gonzalez-Quesada C, Frangogiannis NG. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol 2010;48:504.

[12] Sun Y, Kiani MF, Postlethwaite AE, Weber KT. Infarct scar as living tissue. Basic Res Cardiol 2002;97:343.

[13] Sun Y, Weber KT. Infarct scar: a dynamic tissue. Cardiovasc Res 2000;46:250. [14] Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics--2010 update: a report from the american heart association. Circulation 2010;121:e46.

[15] Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics--2011 update: a report from the american heart association. Circulation 2011;123:e18.

! %)!

[16] Holmes JW, Borg TK, Covell JW. Structure and mechanics of healing myocardial infarcts. Annu Rev Biomed Eng 2005;7:223.

[17] Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007.

[18] Wilson EM, Moainie SL, Baskin JM, Lowry AS, Deschamps AM, Mukherjee R, Guy TS, St John-Sutton MG, Gorman JH, 3rd, Edmunds LH, Jr., Gorman RC, Spinale FG. Region and type specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation 2003;107:2857.

[19] Etoh T, Joffs C, Deschamps AM, Davis J, Dowdy K, Hendrick J, Baicu S, Mukherjee R, Manhaini M, Spinale FG. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am J Physiol Heart Circ Physiol 2001;281:H987.

[20] Guccione JM, Costa KD, McCulloch AD. Finite element stress analysis of left ventricular mechanics in the beating dog heart. J Biomech 1995;28:1167.

[21] Wall ST, Walker JC, Healy KE, Ratcliffe MB, Guccione JM. Theoretical impact of the injection of material into the myocardium: a finite element model simulation. Circulation 2006;114:2627.

[22] Wenk JF, Wall ST, Peterson RC, Helgerson SL, Sabbah HN, Burger M, Stander N, Ratcliffe MB, Guccione JM. A method for automatically optimizing medical devices for treating heart failure: designing polymeric injection patterns. J Biomech Eng 2009;131:121011.

[23] Gupta KB, Ratcliffe MB, Fallert MA, Edmunds LH, Jr., Bogen DK. Changes in passive mechanical stiffness of myocardial tissue with aneurysm formation. Circulation 1994;89:2315.

[24] Ratcliffe MB. Non-ischemic infarct extension: a new type of infarct enlargement and a potential therapeutic target. J Am Coll Cardiol 2002;40:1168.

! %*!

[25] Jackson BM, Gorman JH, 3rd, Salgo IS, Moainie SL, Plappert T, St John-Sutton M, Edmunds LH, Jr., Gorman RC. Border zone geometry increases wall stress after myocardial infarction: contrast echocardiographic assessment. Am J Physiol Heart Circ Physiol 2003;284:H475.

[26] Walker JC, Ratcliffe MB, Zhang P, Wallace AW, Hsu EW, Saloner DA, Guccione JM. Magnetic resonance imaging-based finite element stress analysis after linear repair of left ventricular aneurysm. J Thorac Cardiovasc Surg 2008;135:1094.

[27] Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-inhibitor myocardial infarction collaborative group. Lancet 2000;355:1575. [28] van Zwieten PA. Current and newer approaches in the drug treatment of congestive heart failure. Cardiovasc Drugs Ther 1997;10:693.

[29] Hannan EL, Racz MJ, McCallister BD, Ryan TJ, Arani DT, Isom OW, Jones RH. A comparison of three-year survival after coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1999;33:63.

[30] Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, Culliford AT, Isom OW, Gold JP, Rose EA. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005;352:2174.

[31] John R, Rajasinghe HA, Chen JM, Weinberg AD, Sinha P, Mancini DM, Naka Y, Oz MC, Smith CR, Rose EA, Edwards NM. Long-term outcomes after cardiac transplantation: an experience based on different eras of immunosuppressive therapy. Ann Thorac Surg 2001;72:440.

[32] Goldstein DJ, Oz MC, Rose EA. Implantable left ventricular assist devices. N Engl J Med 1998;339:1522.

! %+!

[33] Padera RF, Jr., Schoen FJ. Cardiovascular medical devices. In: Ratner BD, Hoffman AS, Schoen FJ, Lemons JE, editor. Biomaterials Science, vol. 2. San Diego: Elsevier Academic Press, 2004. p.471.

[34] Zimmermann WH, Didie M, Doker S, Melnychenko I, Naito H, Rogge C, Tiburcy M, Eschenhagen T. Heart muscle engineering: an update on cardiac muscle replacement therapy. Cardiovasc Res 2006;71:419.

[35] Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature 2008;451:937. [36] Zhang G, Nakamura Y, Wang X, Hu Q, Suggs LJ, Zhang J. Controlled release of stromal cell-derived factor-1 alpha in situ increases c-kit+ cell homing to the infarcted heart. Tissue Eng 2007;13:2063.

[37] Abbott JD HY, Hickey R, Krasue DS, Gioedano FJ. Stromal cell-derived factor- 1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 2004;21:3300. [38] Muller-Ehmsen J, Peterson KL, Kedes L, Whittaker P, Dow JS, Long TI, Laird PW, Kloner RA. Rebuilding a damaged heart: long-term survival of transplanted neonatal rat cardiomyocytes after myocardial infarction and effect on cardiac function. Circulation 2002;105:1720.

[39] Hagege AA, Marolleau JP, Vilquin JT, Alheritiere A, Peyrard S, Duboc D, Abergel E, Messas E, Mousseaux E, Schwartz K, Desnos M, Menasche P. Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first phase I cohort of patients. Circulation 2006;114:I108.

[40] Christman KL, Vardanian AJ, Fang Q, Sievers RE, Fok HH, Lee RJ. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol 2004;44:654.

! %,!

[41] Christman KL, Fok HH, Sievers RE, Fang Q, Lee RJ. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng 2004;10:403.

[42] Jing D, Parikh A, Tzanakakis ES. Cardiac cell generation from encapsulated embryonic stem cells in static and scalable culture systems. Cell Transplant 2010;19:1397.

[43] Jing D, Parikh A, Canty JM, Jr., Tzanakakis ES. Stem cells for heart cell therapies. Tissue Eng Part B Rev 2008;14:393.

[44] Kawamoto A, Asahara T, Losordo DW. Transplantation of endothelial progenitor cells for therapeutic neovascularization. Cardiovasc Radiat Med 2002;3:221.

[45] Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, Silver M, Ma H, Kearney M, Isner JM, Asahara T. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001;103:634.

[46] Wang L DJ, Tian W, Xiang, B, Yang, T, Li G, Gruwel M, Kashour T, Rendell J, Glogowski M, Tomanek B, Freed D, Deslaurieres R, Arora RC, Tian G. Adipose-derived stem cells are an effective cell candidate for treatment of heart failure: an MR imaging study of rat hearts. Am J Physiol Heart Circ Physiol 2009;297:H1020.

[47] Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 2004;428:668.

[48] Laflamme MA, Gold J, Xu C, Hassanipour M, Rosler E, Police S, Muskheli V, Murry CE. Formation of human myocardium in the rat heart from human embryonic stem cells. Am J Pathol 2005;167:663.

! %-!

[49] Hodgson DM, Behfar A, Zingman LV, Kane GC, Perez-Terzic C, Alekseev AE, Puceat M, Terzic A. Stable benefit of embryonic stem cell therapy in myocardial infarction. Am J Physiol Heart Circ Physiol 2004;287:H471.

[50] Memon IA, Sawa Y, Fukushima N, Matsumiya G, Miyagawa S, Taketani S, Sakakida SK, Kondoh H, Aleshin AN, Shimizu T, Okano T, Matsuda H. Repair of impaired myocardium by means of implantation of engineered autologous myoblast sheets. J Thorac Cardiovasc Surg 2005;130:1333.

[51] Miyahara Y, Nagaya N, Kataoka M, Yanagawa B, Tanaka K, Hao H, Ishino K, Ishida H, Shimizu T, Kangawa K, Sano S, Okano T, Kitamura S, Mori H. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med 2006;12:459.

[52] Leri A, Kajstura J, Anversa P. Cardiac stem cells and mechanisms of myocardial regeneration. Physiol Rev 2005;85:1373.

[53] Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy and lessons from the heart. Nature 2008;453:322.

[54] Davis ME, Hsieh PC, Takahashi T, Song Q, Zhang S, Kamm RD, Grodzinsky AJ, Anversa P, Lee RT. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci U S A 2006;103:8155.

[55] Kellar RS, Shepherd BR, Larson DF, Naughton GK, Williams SK. Cardiac patch constructed from human fibroblasts attenuates reduction in cardiac function after acute infarct. Tissue Eng 2005;11:1678.

[56] Maulik N, Thirunavukkarasu M. Growth factors and cell therapy in myocardial regeneration. J Mol Cell Cardiol 2008;44:219.

! &.!

[57] Kinnaird T, Stabile E, Epstein SE, Fuchs S. Current perspectives in therapeutic myocardial angiogenesis. J Interv Cardiol 2003;16:289.

[58] Batista R. Partial left ventriculectomy--the Batista procedure. Eur J Cardiothorac Surg 1999;15 Suppl 1:S12.

[59] Ratcliffe MB, Hong J, Salahieh A, Ruch S, Wallace AW. The effect of ventricular volume reduction surgery in the dilated, poorly contractile left ventricle: a simple finite element analysis. J Thorac Cardiovasc Surg 1998;116:566.

[60] Kelley ST, Malekan R, Gorman JH, 3rd, Jackson BM, Gorman RC, Suzuki Y, Plappert T, Bogen DK, Sutton MG, Edmunds LH, Jr. Restraining infarct expansion preserves left ventricular geometry and function after acute anteroapical infarction. Circulation 1999;99:135.

[61] Moainie SL, Guy TS, Gorman JH, 3rd, Plappert T, Jackson BM, St John-Sutton MG, Edmunds LH, Jr., Gorman RC. Infarct restraint attenuates remodeling and reduces chronic ischemic mitral regurgitation after postero-lateral infarction. Ann Thorac Surg 2002;74:444.

[62] Pilla JJ, Blom AS, Brockman DJ, Ferrari VA, Yuan Q, Acker MA. Passive ventricular constraint to improve left ventricular function and mechanics in an ovine model of heart failure secondary to acute myocardial infarction. J Thorac Cardiovasc Surg 2003;126:1467.

[63] Blom AS, Pilla JJ, Gorman RC, 3rd, Gorman JH, Mukherjee R, Spinale FG, Acker MA. Infarct size reduction and attenuation of global left ventricular remodeling with the CorCap cardiac support device following acute myocardial infarction in sheep. Heart Fail Rev 2005;10:125.

! &%!

[64] Klodell CT, Jr., Aranda JM, Jr., McGiffin DC, Rayburn BK, Sun B, Abraham WT, Pae WE, Jr., Boehmer JP, Klein H, Huth C. Worldwide surgical experience with the Paracor HeartNet cardiac restraint device. J Thorac Cardiovasc Surg 2008;135:188. [65] Mann DL, Kubo SH, Sabbah HN, Starling RC, Jessup M, Oh JK, Acker MA. Beneficial effects of the CorCap cardiac support device: five-year results from the Acorn Trial. J Thorac Cardiovasc Surg 2012;143:1036.

[66] Tous E, Purcell B, Ifkovits JL, Burdick JA. Injectable acellular hydrogels for cardiac repair. J Cardiovasc Transl Res 2011;4:528.

! &&!

CHAPTER 2

Research Overview